EichorEICHOR
Study identifier: NCT04363541 Synced from ClinicalTrials.gov · August 04, 2026
● Recruiting

Local Thermotherapy for Patients With Mild-to-moderate COVID-19

Condition: COVID-19 · Thermotherapy  ·  Sponsor: Instituto Nacional de Perinatologia

PhaseNA
Planned participants274
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

The etiological agent of the current pandemic is a (+)ssRNA virus. SARS-CoV-2 is infecting thousands of people in the world with a fatality rate that varies from 0.1 to 5% in affected countries, thereby causing enormous economic losses. Few antibiotics have shown any efficacy in their combat, but have not yet proven adequate to stop the spread of the disease, nor are there any approved vaccines at the moment. From experiments in plants ongoing infections by RNA viruses, using thermotherapy, which is the application of heat at a temperature between 35-43 °C, the investigators know that raising the temperature affects the transcription of viral proteins due to the formation of small RNA molecules that interrupt the replication process by grouping in specific regions of the RNA molecule, preventing and inhibiting transcription. These small molecules are called small interfering RNAs (siRNAs). This feature has been used through thermotherapy in humans to combat the rapid replication of cells (i.e. cancer cells), attack cells infected by RNA viruses, and in the treatment of some parasitic infections.There are various commercially available devices for thermotherapy use in humans; they are mainly being used to ease muscle pain. They work by increasing the temperature in the range recommended for thermotherapy in humans 39-43 ° C. Therefore, the investigators consider this treatment modality can be used to aid in the elimination of SARS-CoV-2 from the human body, decreasing viral lo…

This description comes directly from the study's public registry record.

Talk to the study team

Norma del Carmen Galindo Sevilla, PhD  ·  +525539968217  ·  ngalindosevilla@gmail.com

Javier Mancilla-Galindo, MBBS  ·  javimangal@gmail.com

Always discuss trial participation with your own doctor first.

Locations (3)

Hospital Dr. Ángel LeañoGuadalajara, Jalisco, MexicoRecruiting
Hospital Regional de Alta Especialidad "Dr. Juan Graham Casasus"Villahermosa, Tabasco, MexicoRecruiting
Unidad Temporal Movil COVID-19 Autódromo Hermanos Rodríguez IMSSMexico City, MexicoRecruiting

Follow this study

Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.

We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →